Casma Therapeutics to Present at Oppenheimer Rare & Orphan Disease Summit

b'CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Casma Therapeutics , Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Chief Executive Officer, Keith Dionne, Ph.D., will present a company overview at the upcoming Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 8:15 a.m. ET.\nCasma Therapeutics is harnessing autophagy by developing a novel degradation technology to open new target areas for drug discovery and development that will profoundly impact the lives of patients.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Friday, May 14, 2021

Information

Tags:

Branches of biology, Biology, Cellular processes, Programmed cell death, Autophagy, Cell death, Immunology, Neurodegeneration

Geotags:

Cambridge, Massachusetts, Us

Organisation:

CASMA THERAPEUTICS, INC.

Summary

Key Points:

b'CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Casma Therapeutics , Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Chief Executive Officer, Keith Dionne, Ph.D., will present a company overview at the upcoming Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 8:15 a.m. ET.\nCasma Therapeutics is harnessing autophagy by developing a novel degradation technology to open new target areas for drug discovery and development that will profoundly impact the lives of patients.
Autophagy is a conserved cellular process that contributes to overall organismal health, but when autophagy is perturbed, inefficient autophagic flux contributes to numerous diseases.
By selectively boosting autophagy and degradation of disease targets in the lysosome, Casma expects to be able to arrest or reverse the progression of several diseases such as neurodegeneration, metabolic disorders, inflammation and muscle degeneration.
For more information, please visit www.casmatx.com .\n'

CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Chief Executive Officer, Keith Dionne, Ph.D., will present a company overview at the upcoming Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 8:15 a.m. ET.

About Casma Therapeutics
Casma Therapeutics is harnessing autophagy by developing a novel degradation technology to open new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall organismal health, but when autophagy is perturbed, inefficient autophagic flux contributes to numerous diseases. By selectively boosting autophagy and degradation of disease targets in the lysosome, Casma expects to be able to arrest or reverse the progression of several diseases such as neurodegeneration, metabolic disorders, inflammation and muscle degeneration. For more information, please visit www.casmatx.com.

Contact for Investors and Media

Courteney Backstrom
Casma Therapeutics, Inc.
[email protected]
857-777-4248